Source-grounded facts extracted from Vanda Pharmaceuticals Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Vanda Pharmaceuticals Inc. shareholders approved Amendment to Company's Amended and Restated 2016 Equity Incentive Plan to increase aggregate number of shares authorized for issuance at the 2026-06-04 meeting.
“The Company’s stockholders approved an amendment to the 2016 Plan to increase the aggregate number of shares authorized for issuance under the 2016 Plan.”
Vanda Pharmaceuticals Inc. shareholders approved Advisory vote on named executive officer compensation at the 2026-06-04 meeting.
“The Company’s stockholders approved on an advisory, non-binding basis the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement.”
Vanda Pharmaceuticals Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“The Company’s stockholders ratified the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Vanda Pharmaceuticals Inc. shareholders approved Election of three directors to serve as Class II directors for a term of three years until the Company's 2029 annual meeting of stockholders at the 2026-06-04 meeting.
“The Company’s stockholders elected the following directors to serve as Class II directors until the Company’s 2029 annual meeting of stockholders.”
Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $51.7 million, net income net loss of $48.6 million (diluted loss per share of $0.82), EPS (diluted loss per share of $0.82). Guidance raised.
“pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9”
Vanda Pharmaceuticals Inc.: Amended and restated bylaws with changes to special meeting business scope, advance notice disclosure, meeting adjournment, proxy solicitation, director candidate requirements, and other clarifying updates (effective 2024-10-02).
“On October 2, 2024, the Board of Directors (the "Board") of Vanda Pharmaceuticals Inc. (the "Company") approved an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the "Amended and Restated Bylaws"), effective immediately.”
Vanda Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $47.5 million, net income $(4.1) million.
“Financial Highlights • Total net product sales from Fanapt ® , HETLIOZ ® and PONVORY ® were $47.5 million in the first quarter of 2024, a 24% decrease compared to $62.5 million in the first quarter of 2023, and a 5% increase compared to $45.3 million in the fourth quarter of 2023. • Fanapt ® net product sales were $20.6 million in the first quarter of 2024, a 10% decrease compared to $22.9 million in the first quarter of 2023, and a 9% decrease compared to $22.6 million in the fourth quarter of 2023. • HETLIOZ ® net product sales were $20.1 million in the first quarter of 2024, a 49% decrease compared to $39.6 million in the first quarter of 2023, and a 5% decrease compared to $21.1 million in the fourth quarter of 2023. The decrease relative to the first quarter of 2023 was the result of continued generic competition in the U.S. • PONVORY ® net product sales were $6.8 million in the first quarter of 2024. The acquisition of PONVORY ® from Actelion Pharmaceuticals Ltd. (Janssen), a Joh”
Vanda Pharmaceuticals Inc. amended Amendment No. 1 with Equiniti Trust Company, LLC (effective 2024-05-03).
“On May 3, 2024, Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”), entered into Amendment No. 1 (the “Amendment”) to that certain Rights Agreement, dated as of April 17, 2024 (the “Rights Agreement”), by and between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent.”
Vanda Pharmaceuticals Inc. entered into Rights Agreement with Equiniti Trust Company, LLC (effective 2024-04-17).
“The complete terms of the Rights are set forth in a Rights Agreement (the “Rights Agreement”), dated as of April 17, 2024, between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent.”
Vanda Pharmaceuticals Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 7, 2024, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2023.”
Vanda Pharmaceuticals Inc.: Amended and restated bylaws to address Universal Proxy Rules and conform to Delaware law (effective 2023-12-13).
“On December 13, 2023, the Board of Directors of Vanda Pharmaceuticals Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Fourth Amended and Restated Bylaws (the “Bylaws”).”
Vanda Pharmaceuticals Inc. completed an acquisition involving Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company for $100 million (closed 2023-12-07).
“Vanda made an upfront payment of $100 million to Janssen as consideration for the Purchased Assets.”
Vanda Pharmaceuticals Inc. entered into Purchase Agreement with Actelion Pharmaceuticals Ltd. (Janssen, a Johnson & Johnson Company) valued at $100 million (effective 2023-12-07).
“On December 7, 2023, Vanda Pharmaceuticals Inc. (“Vanda”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Actelion Pharmaceuticals Ltd. (“Janssen”), a Johnson & Johnson Company, pursuant to which Vanda acquired from Janssen the U.S. and Canadian rights for PONVORY ® (ponesimod).”
Vanda Pharmaceuticals Inc. reported the third quarter ended September 30, 2023 results: revenue $38.8 million, net income $0.1 million.
“Total net product sales from HETLIOZ ® and Fanapt ® were $38.8 million in the third quarter of 2023”
Vanda Pharmaceuticals Inc. reported first six months of 2023 results: revenue $108.6 million, net income $4.8 million, EPS $0.08.
“First Six Months of 2023 • Total net product sales from HETLIOZ ® and Fanapt ® were $108.6 million in the first six months of 2023, a 13% decrease compared to $124.6 million in the first six months of 2022. • HETLIOZ ® net product sales were $61.6 million in the first six months of 2023, a 21% decrease compared to $78.2 million in the first six months of 2022. The decrease was the result of the at-risk launch of a generic version of HETLIOZ ® in the U.S. • Fanapt ® net product sales were $47.0 million in the first six months of 2023, a 1% increase compared to $46.4 million in the first six months of 2022. • Net income was $4.8 million in the first six months of 2023 compared to a net loss of $3.9 million in the first six months of 2022. • Cash, cash equivalents and marketable securities (Cash) was $489.4 million as of June 30, 2023, representing an increase to Cash of $48.5 million, or 11%, compared to June 30, 2022. Key Operational Highlights Fanapt ® (iloperidone) • Vanda previously”
Vanda Pharmaceuticals Inc. reported second quarter 2023 results: revenue $46.1 million, net income $1.5 million, EPS $0.03.
“Financial Highlights Second Quarter of 2023 • Total net product sales from HETLIOZ ® and Fanapt ® were $46.1 million in the second quarter of 2023, a 28% decrease compared to $64.4 million in the second quarter of 2022. • HETLIOZ ® net product sales were $22.0 million in the second quarter of 2023, a 47% decrease compared to $41.2 million in the second quarter of 2022. The decrease was the result of the at-risk launch of a generic version of HETLIOZ ® in the U.S. • Fanapt ® net product sales were $24.1 million in the second quarter of 2023, a 4% increase compared to $23.2 million in the second quarter of 2022. • Net income was $1.5 million in the second quarter of 2023 compared to net income of $2.6 million in the second quarter of 2022. • Cash, cash equivalents and marketable securities (Cash) was $489.4 million as of June 30, 2023, representing a decrease to Cash of $12.1 million, or 2%, compared to March 31, 2023. First Six Months of 2023 • Total net product sales from HETLIOZ ® and”
Vanda Pharmaceuticals Inc. shareholders approved Amendment to Amended and Restated 2016 Equity Incentive Plan to increase authorized shares at the 2023-06-08 meeting.
“Proposal 5: Amendment to the Company’s Amended and Restated 2016 Equity Incentive Plan. The Company’s stockholders approved an amendment to the Company’s Amended and Restated 2016 Equity Incentive Plan to increase the aggregate number of shares authorized for issuance under the Amended and Restated 2016 Equity Incentive Plan. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 43,677,992 5,025,559 6,202 3,907,048”
Vanda Pharmaceuticals Inc. shareholders approved Frequency of future advisory votes on named executive officer compensation (1 year preferred) at the 2023-06-08 meeting.
“Proposal 4: Frequency of Future Advisory Votes on Named Executive Officer Compensation. The Company’s stockholders approved the option of holding an advisory non-binding vote to approve the compensation of the Company’s named executive officers once every “1 Year.” The votes regarding this proposal were as follows: 1 Year 2 Years 3 Years Votes Abstaining Broker Non-Votes 44,614,824 154,140 3,934,630 6,159 3,907,048”
Vanda Pharmaceuticals Inc. shareholders approved Advisory approval of named executive officer compensation at the 2023-06-08 meeting.
“Proposal 3: Advisory Vote on Named Executive Officer Compensation. The Company’s stockholders approved on an advisory non-binding basis the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 47,007,380 1,536,842 165,531 3,907,048”
Vanda Pharmaceuticals Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-08 meeting.
“Proposal 2: Ratification of Selection of PricewaterhouseCoopers LLP. The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining 52,035,525 566,066 15,210”
Vanda Pharmaceuticals Inc. shareholders approved Election of two Class II directors for a term of three years until the 2026 annual meeting at the 2023-06-08 meeting.
“Proposal 1: Election of Directors. The Company’s stockholders elected the following directors to serve as Class II directors until the 2026 annual meeting of stockholders. The votes regarding the election of directors were as follows: Director Votes For Votes Against Votes Abstaining Broker Non-Votes Richard W. Dugan 43,447,760 5,253,100 8,893 3,907,048 Anne Sempowski Ward 47,111,880 1,589,271 8,602 3,907,048”
Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2023 results: revenue $62.5 million, net income $3.3 million, EPS diluted net income per share was $0.06.
“set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results • Q1 2023 total revenues were $62.5 million • Vanda provides update on three upcoming regulatory submissions WASHINGTON – May 3, 2023 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and”
Tage Honoré was appointed as director at Vanda Pharmaceuticals Inc..
“On March 15, 2023, the Board of Directors (the “Board”) of Vanda Pharmaceuticals Inc. (the “Company”) expanded the size of the Board from five to six members, effective immediately and appointed Tage Honoré, Ph.D., D.Sc., as a director of the Company to fill the vacancy created by the expansion.”
Vanda Pharmaceuticals Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $254.4 million, net income $6.3 million, EPS $0.11.
“Total net product sales from HETLIOZ ® and Fanapt ® were $64.5 million in the fourth quarter of 2022”
Vanda Pharmaceuticals Inc. reported full year 2022 results: revenue $240 to $270 million. Guidance lowered.
“Vanda is updating its 2022 financial guidance and expects to achieve the following financial objectives in 2022 : Full Year 2022 Financial Objectives Revised Full Year 2022 Guidance Prior Full Year 2022 Guidance Total revenues $240 to $270 million $240 to $280 million HETLIOZ ® net product sales $150 to $170 million $150 to $180 million Fanapt ® net product sales $90 to $100 million $90 to $100 million Year-end 2022 Cash Greater than $450 million Greater than $440 million”
Vanda Pharmaceuticals Inc. reported third quarter ended September 30, 2022 results: net income $3.3 million, EPS $0.06.
“Net income was $3.3 million in the third quarter of 2022 compared to net income of $7.8 million in the third quarter of 2021. Diluted net income per share was $0.06 in the third quarter of 2022 compared to diluted net income per share of $0.14 in the third quarter of 2021.”
Aranthan "AJ" Jones II resigned as Chief Corporate Affairs and Communications Officer at Vanda Pharmaceuticals Inc..
“Mr. Jones resigned as the Company’s Chief Corporate Affairs and Communications Officer effective as of October 26, 2021.”
H. Thomas Watkins resigned as Class I director at Vanda Pharmaceuticals Inc..
“H. Thomas Watkins notified the Board that he would resign from the Board as a Class I director effective as of the Company’s 2022 Annual Meeting of Stockholders”
Aranthan Jones II resigned as Corporate Affairs and Communications Officer at Vanda Pharmaceuticals Inc..
“On October 6, 2021, Aranthan “AJ” Jones II notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Corporate Affairs and Communications Officer, effective as of October 26, 2021, in order to join a U.S.-based, publicly traded company outside of the biopharmaceutical sector.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.